The stories behind the advances in polycythemia vera
Ongoing data from the phase 3 RESPONSE trial of ruxolitinib for polycythemia vera
What is the unmet medical need of patients with PV and ET?
Haifa Kathrin Al-Ali
MAJIC trial results: ruxolitinib compared to best available therapy for essential thrombocythemia
PROUD-PV and MPD-RC 112 trials of interferon alpha vs hydroxyurea for MPNs